Invasive Aspergillosis Clinical Trial
Official title:
Diagnosing Invasive Aspergillosis by PCR Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in
patients (pts) with hematologic malignancies. As culture-based methods only yield results in
a minority of patients, using non-culture-based methods for detection of aspergillosis in
clinical specimens becomes increasingly important. Analyzing bronchoalveolar lavage (BAL)
samples with polymerase chain reaction (PCR) is promising, however, the influence of current
antifungal drugs on the performance of this diagnostic tool remains controversial.
The aim of the trial is to elucidate on the performance of BAL PCR under antifungal
treatment.
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in
patients (pts) with hematologic malignancies. As culture-based methods only yield results in
a minority of patients, using non-culture-based methods for detection of aspergillosis in
clinical specimens becomes increasingly important. Analyzing bronchoalveolar lavage (BAL)
samples with polymerase chain reaction (PCR) is promising, however, the influence of current
antifungal drugs on the performance of this diagnostic tool remains controversial.
The aim of the trial is to elucidate on the performance of BAL PCR under antifungal
treatment.
Patients with high risk of invasive aspergillosis and lung infiltrates are sampled via BAL,
the sample is analyzed for fungal DNA by Apsergillus specific PCR. Clinical data including
treatment data is assessed and evaluated.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
|
||
| Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
| Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
| Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
| Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
| Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
| Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
| Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
| Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
| Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
| Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
| Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
| Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
| Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
| Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
| Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
| Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
| Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
| Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 |